v3.26.1
Shareholders' Equity - Sale of shares (Details)
$ / shares in Units, € in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2024
shares
Oct. 25, 2024
EUR (€)
shares
Oct. 25, 2024
USD ($)
shares
Jun. 30, 2026
EUR (€)
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Apr. 30, 2026
USD ($)
$ / shares
shares
Oct. 31, 2024
EUR (€)
shares
Oct. 31, 2024
USD ($)
$ / shares
shares
Jun. 30, 2026
EUR (€)
Jun. 30, 2026
EUR (€)
shares
Sep. 30, 2024
USD ($)
Disclosure of classes of share capital [line items]                      
Net proceeds from issuing shares | €                 € 49,201 € 49,201  
2024 shelf registration statement                      
Disclosure of classes of share capital [line items]                      
Maximum offering price in shelf registration statement | $                     $ 300,000,000
At the market offerings with Cantor Fitzgerald and Co under shelf registration statement                      
Disclosure of classes of share capital [line items]                      
Maximum offering price in shelf registration statement | $                     $ 75,000,000
Percentage of commission payable for gross proceeds from sales agreement                     3.00%
Issue of ordinary shares (in shares)                   0  
October 2024 underwritten public offering                      
Disclosure of classes of share capital [line items]                      
Issue of ordinary shares (in shares)             18,000,000 18,000,000      
Price per share | $ / shares               $ 3.5      
Proceeds from issuing shares             € 64,600 $ 69,790,000      
Payments for share issue costs | €             4,365        
Net proceeds from issuing shares | €             € 60,235        
Underwriters' option in connection to October 2024 underwritten public offering                      
Disclosure of classes of share capital [line items]                      
Issue of ordinary shares (in shares) 1,940,072                    
Duration of underwriters' option             30 days 30 days      
Number of shares callable for options issued 2,700,000           2,700,000 2,700,000      
Share purchase agreement with Eli Lilly and Company                      
Disclosure of classes of share capital [line items]                      
Issue of ordinary shares (in shares)   3,523,538 3,523,538 5,100,780 5,100,780            
Proceeds from issuing shares   € 11,400 $ 12,300,000 € 8,100 $ 9,200,000            
Purchase price cap, share purchase agreement | $     $ 15,000,000                
Share purchase agreement with Ginkgo Bioworks                      
Disclosure of classes of share capital [line items]                      
Issue of ordinary shares (in shares)           3,030,303          
Reference price per share | $ / shares           $ 1.65          
Contractual credit received as consideration for shares issued | $           $ 5,000,000          
Contractual term over which credit can be utilized           3 years          
June 2026 underwritten public offering                      
Disclosure of classes of share capital [line items]                      
Issue of ordinary shares (in shares)       27,624,310 27,624,310            
Price per share | $ / shares         $ 1.81            
Proceeds from issuing shares       € 44,100 $ 50,000,000            
Payments for share issue costs | €       3,000              
Net proceeds from issuing shares | €       € 41,100